Barrow Neurological Institute

Running trials

• Not yet recruiting

  Safety Study of XT-150 in Participants With ALS

  NCT06704347· Phase 1· Xalud Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)

  NCT07282847· Phase 1/2· AskBio Inc· Source

• Recruiting

  The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

  NCT07143019· phenox Inc.· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Coya Therapeutics· Source

• Not yet recruiting

  Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

  NCT06973629· Phase 3· Brainstorm-Cell Therapeutics· Source

• Recruiting

  EIM Via the Myolex mScan as an ALS Biomarker

  NCT06491732· Beth Israel Deaconess Medical Center· Source

• Recruiting

  Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

  NCT06847321· Phase 2· Lighthouse Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

  NCT06765668· Phase 4· Impax Laboratories, LLC· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Enrolling by invitation

  Control of Assistive Devices Via Brain-Computer Interface Technology

  NCT06710626· Neuralink Corp· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Active, not recruiting

  Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population

  NCT06293482· Cochlear· Source

• Recruiting

  Working Memory Training in Patients with Mild Cognitive Impairment

  NCT06734286· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Active, not recruiting

  Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

  NCT06100276· Phase 1/2· UniQure Biopharma B.V.· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  ASSESS ALL ALS Study

  NCT06578195· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Active, not recruiting

  PREVENT ALL ALS Study

  NCT06581861· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Active, not recruiting

  Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

  NCT06106672· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Cognito Therapeutics, Inc.· Source

• Recruiting

  Precise Robotically IMplanted Brain-Computer InterfacE

  NCT06429735· Neuralink Corp· Source

• Recruiting

  Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

  NCT05866419· Alcyone Therapeutics, Inc· Source

• Enrolling by invitation

  Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· University of Southern California· Source

• Recruiting

  Time Restricted Eating in Alzheimer's Disease

  NCT06429124· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Active, not recruiting

  Pilot/Pivotal Study of DBS+Rehab After Stroke

  NCT05701280· Enspire DBS Therapy, Inc.· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

• Recruiting

  [18F]PI-2620 Phase 3 Histopathological Study

  NCT05641688· Phase 3· Lantheus Biosciences Ltd.· Source

• Active, not recruiting

  Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

  NCT05382156· RECORDATI GROUP· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

  NCT05067790· Phase 3· Biogen· Source

• Recruiting

  Trial-Ready Cohort-Down Syndrome (TRC-DS)

  NCT04165109· University of Southern California· Source

• Recruiting

  Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

  NCT05137665· Target ALS Foundation, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

  NCT04916210· Massachusetts General Hospital· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

• Active, not recruiting

  A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

  NCT04093349· Phase 1/2· Spark Therapeutics, Inc.· Source

• Active, not recruiting

  Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

  NCT04195568· Stryker Neurovascular· Source

• Recruiting

  PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

  NCT04477785· Michael J. Fox Foundation for Parkinson's Research· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  Spinraza in Adult Spinal Muscular Atrophy

  NCT03709784· Washington University School of Medicine· Source

• Active, not recruiting

  Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

  NCT02685605· Phase 3· Universitätsmedizin Mannheim· Source

• Active, not recruiting

  Biobank For MS And Other Demyelinating Diseases

  NCT00445367· Accelerated Cure Project for Multiple Sclerosis· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Genzyme, a Sanofi Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)8 recruiting
• Alzheimer disease7 recruiting
• Parkinson disease4 recruiting
• Pompe disease2 recruiting
• Spinal cord injury2 recruiting
• Stroke2 recruiting
• Brain aneurysm1 recruiting
• Down syndrome1 recruiting
• Epilepsy1 recruiting
• Frontotemporal dementia1 recruiting
• Spinal muscular atrophy1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

  NCT06235190· Fasikl Inc.· Source

• Completed

  Early Parkinson's Disease Monotherapy With CVN424

  NCT06006247· Phase 2· Cerevance Beta, Inc.· Source

• Terminated

  LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

  NCT06860373· Phase 3· LuMind IDSC Foundation· Source

• Completed

  RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

  NCT05869669· Phase 2· EIP Pharma Inc· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Cognito Therapeutics, Inc.· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Recruiting

  A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

  NCT05462106· Phase 1/2· AC Immune SA· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

  NCT05225415· Phase 2· Cognition Therapeutics· Source

• Completed

  Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

  NCT05216250· Phase 2· AbbVie· Source

• Completed

  Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

  NCT05232929· Phase 4· Genentech, Inc.· Source

• Completed

  Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

  NCT05216263· Phase 3· AbbVie· Source

• Completed

  Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

  NCT05276349· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Completed

  Osia 2 Pediatric Expansion Study

  NCT05000931· Cochlear· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source

• Terminated

  Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

  NCT05028569· Phase 3· AbbVie· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

  NCT04602390· Phase 1· Anokion SA· Source

• Terminated

  A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

  NCT04494256· Phase 1/2· Biogen· Source

• Completed

  Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

  NCT04377555· Phase 4· Genentech, Inc.· Source

• Completed

  Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

  NCT04259255· Shionogi· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Functional Neuromodulation Ltd· Source

• Terminated

  Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

  NCT04149197· LuMind IDSC Foundation· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· University of Southern California· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· NovoCure GmbH· Source

• Completed

  Modifiers of Disease Severity in Cerebral Cavernous Malformations

  NCT01764529· University of California, San Francisco· Source

• Completed

  A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

  NCT00676715· Phase 2· Genentech, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease85 works · 15 trials
• Brain aneurysm30 works · 2 trials
• ALS (motor neurone disease)24 works · 15 trials
• Migraine17 works · 4 trials
• Hydrocephalus13 works · 0 trials
• Lewy body dementia10 works · 2 trials
• Frontotemporal dementia8 works · 2 trials
• Meningioma8 works · 0 trials
• Essential tremor6 works · 2 trials
• Trigeminal neuralgia4 works · 0 trials
• Multiple system atrophy3 works · 0 trials